Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Huanghe Road Site) – FDA 483, Jul 16, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd. received a Form FDA 483 with three observations related to manufacturing sterile drug products. The firm failed to establish adequate procedures for preventing microbiological contamination and validating sterilization processes, particularly concerning airflow visualization studies. Additionally, the quality control unit lacked proper oversight, resulting in missing records and significant errors in batch production records, and master production records were deficient in manufacturing instructions and specifications.
- Inspection date
- July 16, 2026
- Product type
- drugs
ID · dcfc67cd-7925-46e3-aa1d-6a3ada69852e
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.